Drug Profile
Research programme: COVID-2019 therapeutics - Green Cross LabCell/Biohaven Labs
Latest Information Update: 29 Jan 2021
Price :
$50
*
At a glance
- Originator Green Cross LabCell; Kleo Pharmaceuticals
- Developer Biohaven Labs; Green Cross LabCell
- Class Natural killer cell therapies
- Mechanism of Action Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 07 Jan 2021 Kleo Pharmaceuticals was acquired and merged into Biohaven Pharmaceutical Holding Company to form Biohaven Labs
- 31 Mar 2020 Kleo Pharmaceuticals and Green ross LabCell collaborate to co-develop therapies for COVID-2019 infections
- 31 Mar 2020 Early research in COVID-2019 infections (Combination therapy) in South Korea (Parenteral)